Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Breast Cancer
Interventions
BIOLOGICAL

herceptin

DRUG

carboplatin

DRUG

docetaxel

PROCEDURE

conventional surgery

Modified radical mastectomy or lumpectomy and axillary node dissection

PROCEDURE

radiation therapy

Whole breast or chest wall irradiation (as determined by radiologist)

Trial Locations (9)

08816

Central Jersey Oncology Center, PA - East Brunswick, East Brunswick

07728

CentraState Medical Center, Freehold

08690

Cancer Institute of New Jersey at Hamilton, Hamilton

07042

Mountainside Hospital Cancer Center, Montclair

07962-1956

Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown

08901-1780

Saint Peter's University Hospital, New Brunswick

08903

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick

07103

UMDNJ University Hospital, Newark

07902-0220

Overlook Hospital, Summit

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

University of Medicine and Dentistry of New Jersey

OTHER